People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Coya Therapeutics, Inc. | — | Biotechnology | Series B | $56.9M | $62.3M | 2022 |
Adrian Hepner at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adrian Hepner on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dov Goldstein | 1 | 6 |
| David Snyder | 1 | 5 |
| Dieter Weinand | 1 | 4 |
| Shawn M Titcomb | 1 | 3 |
| Hideki Garren | 1 | 2 |
| Howard Berman | 1 | 1 |
| Arun Swaminathan | 1 | 1 |
| Greg MacMichael | 1 | 1 |
| Andrea Goldstein | 1 | 1 |
| Jani Tuomi | 1 | 1 |
| Anabella Villalobos | 1 | 1 |
| Ann Lee | 1 | 1 |
| Fred Grossman | 1 | 1 |
| Wilbur Ross | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.